RESUMEN
Objective At present, there are few studies on the application of intensity-modulated radiation therapy (IMRT) combined with chemotherapy in the treatment of non-small cell carcinoma (NSCLC). The article aimed to analyze the efficacy of chemotherapy combined with IMRT on patients with locally advanced NSCLC and the impact on life quality.Methods From January 2012 to December 2014, 160 patients with locally advanced NSCLC were treated in our department of radiotherapy. The patients were divided into IMRT group(chemotherapy of paclitaxel or gemcitabine combined with cisplatin, IMRT) and control group(chemotherapy of paclitaxel or gemcitabine combined with cisplatin) according to different treatments, 80 patients in each group. The patients′ treatment efficacy along with its impact on the patients′ life quality were compared between two groups.Results The effective rate of IMRT group was higher than that of control group(78.75% vs 47.50%, P0.05). Conclusion Chemotherapy combined with IMRT can significantly improve the therapeutic effect in patients with locally advanced NSCLC, featuring less side effects, high safety, improved life quality and lengthened survival time. Therefore, the treatment is worthy of clinical application.
RESUMEN
<p><b>BACKGROUND AND OBJECTIVE</b>Recently, the theory of cancer stem cells (CSCs) has presented new targets and orientations for tumor therapy. The major difficulties in researching CSCs include their isolation and purification. The aim of this study is to identify and characterize the side population (SP) cells in small cell lung cancer (SCLC) cell line H446, which lays the foundation for the isolation and purification of CSCs.</p><p><b>METHODS</b>Fluorescence-activated cell sorting (FACS) was used to sort SP and non-SP (NSP) cells from H446. Both subgroups were cultivated to survey the capacity to form into suspended tumor cell spheres. Reverse transcription-polymerase chain reaction (RT-PCR) and real-time PCR were used to evaluate the expression levels of the mRNA of CD133, ABCG2, and nucleostemin in both subgroups. The capacity of proliferation and the differences in drug resistance of both subgroups and unsorted cells were tested by the MTT method. The differentiation ability of both subgroups was determined by FACS. Proliferation was determined by subcutaneous tumor formation in nude mice.</p><p><b>RESULTS</b>The percent of Hoechst 33342 negative cells was about (5.1 +/- 0.2)% in H446 by fluorescence microscopy. The percent of SP cells was (6.3 +/- 0.1)% by flow cytometry. SP cells had a stronger capability of forming into tumor spheres than NSP cells. The mRNA expression levels of ABCG2, CD133, and nucleostemin in SP cells were 21.60 +/- 0.26, 7.10 +/- 0.14, and 1.02 +/- 0.08 folds higher than that in NSP cells (P < 0.01, P < 0.01, and P > 0.05, respectively). In vivo, SP cells showed better proliferative ability and tougher viability when treated with drugs. SP cells can differentiate into NSP cells, but NSP cells cannot differentiate into SP cells. SP cells had a greater ability to form tumors.</p><p><b>CONCLUSION</b>The H446 cell line contained some SP cells with stem cell properties. CD133 and ABCG2 may be cancer stem cell markers of SCLC.</p>